Engineered immune cells for advanced cancer with KRAS mutation
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests an experimental treatment that uses your own immune cells (T cells) that have been specially changed to attack cancer cells with a certain genetic mutation (KRAS G12D). It may be an option for people with advanced cancer that has not responded to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of cancer that is advanced or has spread, such as colorectal, pancreatic, lung, stomach, small bowel, appendix, or bile duct cancer.
- Your tumor must have a specific change called the KRAS G12D mutation, confirmed by a certified lab test.
- A blood test (HLA typing) must show that you have the HLA-A11:01 or HLA-C08:02 marker.
- You must have already tried at least one standard treatment for your cancer, depending on the type (for example, certain chemotherapy, immunotherapy, or targeted therapy).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment made from your own immune cells that are specially trained to attack cancer cells with a specific mutation called KRAS G12V. It is for people with advanced solid tumors who have run out of standard options.
This trial tests a new type of immune cell therapy (TCR T cells) designed to target a specific KRAS mutation (G12V) in certain advanced cancers. It may be an option for people with pancreatic, bile duct, colorectal, or lung cancer who have already tried standard treatments.
This trial tests a new pill (LY3962673) for people whose cancer has a specific DNA change called KRAS G12D. The drug aims to block the faulty protein that helps the cancer grow, and the study will look at safety and whether the tumor shrinks.
This trial tests a cancer vaccine designed to target KRAS-mutated tumors, combined with two immunotherapy drugs, for people with advanced colorectal or pancreatic cancer. It may help the immune system recognize and attack cancer cells.
This Phase 1/2 study tests a lab-made immune cell (T-cell) treatment that targets a specific KRAS mutation (G12V) found in some pancreatic cancers. It may help shrink tumors or control cancer growth after standard treatment, and it mainly focuses on safety and early effectiveness.
This trial tests a personalized T-cell therapy designed to target pancreatic cancer cells that have a specific KRAS mutation (G12V or G12D). It is for people whose cancer has spread or is locally advanced and who have already benefited from standard treatments.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.